Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Wednesday morning. The brokerage issued a sell rating on the stock.

Oragenics Stock Up 2.0 %

NYSE:OGEN opened at $0.29 on Wednesday. Oragenics has a twelve month low of $0.25 and a twelve month high of $7.74. The firm has a market capitalization of $3.49 million, a price-to-earnings ratio of -0.04 and a beta of 0.49. The stock’s 50 day moving average price is $0.37 and its two-hundred day moving average price is $1.01.

Institutional Investors Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC purchased a new position in shares of Oragenics, Inc. (NYSE:OGEN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned about 0.51% of Oragenics as of its most recent SEC filing. 18.71% of the stock is currently owned by institutional investors and hedge funds.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.